Evidence-based compounding
Assessment of compatibility, dosage form, preservation, stability rationale, process and documentation.
Explore →SIKALIAS
Scientific Practice
The scientific practice of Stasinos Chr. Sikalias across compounding, pharmaceutical care, formulation development and scale-up.
Pharmaceutical care
Structured pharmacist contribution to safe, understandable and practical day-to-day treatment use.
Explore →Formulation development
Translation of a client brief into a technically feasible formulation and development plan.
Explore →Scale-up & manufacturing readiness
Process understanding, critical parameters, analytical support and technical handover.
Explore →The feedback loop
Community pharmacy reveals unmet needs and recurring failure patterns. Industrial R&D adds process discipline, analytical thinking and scale-up awareness. The two environments reinforce one another when confidentiality, professional boundaries and evidence limitations are respected.
SPECIALIST COLLABORATION
Allergen compounding & paediatric-allergy collaboration
My compounding experience at Sikalias Pharmacy includes allergen-containing preparations, including peanut and pistachio formulations, for individually assessed cases managed under the strict supervision of paediatric allergists. The pharmacy’s contribution concerns the preparation; patient selection, treatment decisions and clinical monitoring belong to the specialist team.
This work brings formulation questions, preparation records and clear professional responsibilities into the same conversation. Clinical outcomes must be assessed individually; no general claim of permanent immunity or guaranteed success is made.
The Formulary as a living scientific resource
The Greek Formulary Sikalias brings source review, editorial status and preparation records together. Its current edition belongs at compounding.gr; the knowledge hub explains how to use it responsibly.
Read the current resource guideSIKALIAS PHARMACEUTICAL LABORATORIES
Turn a scientific question into a development brief.
Discuss formulation R&D, technology transfer, CMO / CDMO or European nearshoring with the Laboratories. Start with a non-confidential outline of your dosage form, development stage, target market and volume.